Xiaonan Mei
University of Kentucky
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xiaonan Mei.
Clinical Transplantation | 2016
Moises A. Huaman; Valery Vilchez; Xiaonan Mei; Daniel L. Davenport; Roberto Gedaly
The effect of blood culture positive donor (BCPD) on delayed graft function (DGF) in kidney transplant recipients has not been well established.
Journal of Surgical Oncology | 2017
Leonardo Garcia Atienza; Jonathan Berger; Xiaonan Mei; Malay Shah; Alla Grigorian; Roberto Gedaly
Fibrolamellar Hepatocellular Carcinoma (FL‐HCC) is a rare primary liver tumor that usually presents in younger patients without underlying liver disease.
Liver International | 2016
Cristin Coquillard; Jonathan Berger; Malay Shah; Xiaonan Mei; Francesc Marti; Roberto Gedaly
The purpose of this study was to evaluate predictors of outcomes in combined liver–kidney transplants for polycystic liver and kidney disease.
Transplant International | 2017
Moises A. Huaman; Valery Vilchez; Xiaonan Mei; Malay Shah; Jonathan Berger; Roberto Gedaly
Liver transplantation using blood culture positive donors (BCPD) has allowed a significant expansion of the donor pool. We aimed to characterize BCPD and assess the outcomes of BCPD liver transplant recipients. We retrieved data from the United Network for Organ Sharing (UNOS) registry on all adults who underwent primary, single‐organ deceased‐donor liver transplantation in the USA between 2008 and 2013. Patients were classified into two cohorts: the BCPD cohort and the non‐BCPD cohort. One‐year graft and patient survival were compared between cohorts using Kaplan–Meier estimates and Cox models. A total of 28 961 patients were included. There were 2316 (8.0%) recipients of BCPD. BCPD were more likely to be older, female, black, diabetic, hypertensive, and obese compared to non‐BCPD. Graft survival was significantly lower in BCPD recipients compared to non‐BCPD recipients (Kaplan–Meier, 0.85 vs. 0.87; P = 0.009). Results remained significant in propensity‐matched analysis (P = 0.038). BCPD was independently associated with decreased graft survival (adjusted HR; 1.10, 95% CI 1.01–1.20; P = 0.04). There were no significant differences in patient survival between study groups. BCPD was associated with decreased graft survival in liver transplant recipients. Studies are needed to identify subgroups of BCPD with the highest risk of graft failure and characterize the underlying pathogenic mechanisms.
Transplantation | 2017
Catherine R. Garcia; Luis F. Acosta; Xiaonan Mei; Jonathan Berger; Malay Shah; Alla Grigorian; Roberto Gedaly
Background Liver transplantation (LT) is rarely indicated in the management of iatrogenic bile duct injuries (IBDI), but occasionally, it becomes the only remaining therapy. The purpose of this study is to evaluate potential complications of IBDI and their impact on perioperative mortality, graft, and patient survival after LT. Methods The United Network for Organ Sharing database was queried for all LT performed in the United States between 1994 and 2014. Of the 101 238 liver transplants performed, 61 were related to IBDI. We performed a case matched analysis in a 5:1 ratio. Results The median age for patients with IBDI was 50.16 ± 11.7 years with a mean Model End-Stage Liver Disease score of 22.6 ± 9.8. Patients receiving LT for IBDI were more likely women (54.1%, P = 0.001), had lower incidence of hepatitis C virus infection (4.9%, P = 0.001) and longer cold ischemic time (P = 0.001). The mean body mass index was 25.5 ± 5.2 in patients transplanted for IBDI. IBDI was recognized as the strongest independent predictor associated with eightfold increased risk of early graft loss (P = 0.001; odds ratio, 8.4) and a 2.9-fold increased risk of 30-day mortality after LT in a case matched analysis (P = 0.03). Conclusions IBDI is an uncommon but challenging indication for LT. These patients have significantly increased rates of early graft loss. IBDI is an independent factor related to increased risk of perioperative death after LT. Further studies are needed to determine the causes of perioperative complications and identify potential modifiable factors to improve outcomes in patients undergoing transplantation for IBDI.
Clinical Transplantation | 2017
Amr El-Husseini; A. Aghil; J. Ramirez; B. Sawaya; Navin Rajagopalan; M. Baz; Xiaonan Mei; Daniel L. Davenport; Roberto Gedaly
The number of nonrenal solid‐organ transplants increased substantially in the last few decades. Many of these patients develop renal failure and receive kidney transplantation. The aim of this study was to evaluate patient and kidney allograft survival in primary, repeat, and kidney‐after‐nonrenal organ transplantation using national data reported to United Network for Organ Sharing (UNOS) from January 2000 through December 2014. Survival time for each patient was stratified into the following: Group A (comparison group)—recipients of primary kidney transplant (178 947 patients), Group B—recipients of repeat kidney transplant (17 819 patients), and Group C—recipients of kidney transplant performed after either a liver, heart, or lung transplant (2365 patients). We compared survivals using log‐rank test. Compared to primary or repeat kidney transplant, patient and renal allograft survival was significantly lower in those with previous nonrenal organ transplant. Renal allograft and patient survival after liver, heart, or lung transplants are comparable. Death was the main cause of graft loss in patients who had prior nonrenal organ transplant.
World Journal of Surgery | 2016
Pooja Kanthawar; Xiaonan Mei; Jyotin Chandarana; Malay Shah; Jonathan Berger; Ana Lia Castellanos; Francesc Marti; Roberto Gedaly
World Journal of Surgery | 2018
Shu Kwun Lui; Catherine R. Garcia; Xiaonan Mei; Roberto Gedaly
Transplantation direct | 2018
Amr El-Husseini; Sherif Saleh; Omer Hamad; Xiaonan Mei; Ana Lia Castellanos; Daniel L. Davenport; Roberto Gedaly; B. Peter Sawaya
Hpb | 2017
C. Garcia; Xiaonan Mei; Jonathan Berger; Malay Shah; Roberto Gedaly